As AI continues to gain traction in market access, pricing, value, and HEOR functions, what are the potential wins and key opportunities for success? What should leaders be mindful of? 

Moderated by Product Owner, Thomas Gilboy, we were joined by Joao Carrasco from Bayer Pharmaceuticals, Katja Berg from AstraZeneca and Marco Rauland from Merck KGaA . Learn more about the panellists below. 

Together, they shared their own views and experiences to examine who is embracing AI and who remains sceptical and looked to uncover the current state of AI in market access today.